Cyanopyridine derivative and use thereof as medicine
申请人:Morioka Masahiko
公开号:US20090292121A1
公开(公告)日:2009-11-26
A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.
[EN] COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉ UTILISÉ COMME INHIBITEUR DE KINASE RET ET SON UTILISATION<br/>[ZH] 用作RET激酶抑制剂的化合物及其应用
CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE
申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP1876178B1
公开(公告)日:2015-05-27
COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF
申请人:TYK MEDICINES, INC.
公开号:US20220233513A1
公开(公告)日:2022-07-28
The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I′), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol therein is as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has better pharmacokinetic properties.